| |
|
Product Name:
|
Type Strain, Adapted in Rhesus Monkey
|
|
Ownership statement:
|
This reagent is the tangible property of the U.S. Government.
|
|
Manufacturer:
|
Jennifer A. Manuzak, PhD, Division of Immunology, Tulane National Primate Research Center, Covington, Louisiana
|
|
Taxonomy:
|
Protozoa Classification: PIasmodiidae, Plasmodium
Species: Plasmodium fragile
|
|
Additional Information:
|
P. fragile is a protozoan parasite from New World monkeys that shares close relationships to Plasmodium vivax. The type strain of P. fragile can induce clinical symptoms, including cerebral malaria in rhesus macaques, that resemble those of P. falciparum infection in humans. P. fragile can be continuously cultured in vitro and has been frequently used for drug and vaccine studies.3,4
|
|
Material Provided:
|
Each vial of MRA-1322 contains approximately 1.0 mL of P. fragile-infected rhesus monkey blood in Glycerolyte solution. This item is host restricted and must be amplified in monkeys.
|
|
Packing/Storage:
|
MRA-1322 was packaged aseptically in cryovials. The product is provided frozen and should be stored at -80°C or colder immediately upon arrival. For long-term storage, the vapor phase of a liquid nitrogen freezer is recommended (-130°C or colder). Freeze-thaw cycles should be avoided.
|
|
Growth Conditions:
|
Grows in vitro in erythrocytes of Macaca mulatta and in vivo in Macaca sinica Alternate host: Aotus and Saimiri monkeys
|
|
Disclaimers:
|
You are authorized to use this product for research use only. It is not intended for human use. Use of this product is subject to the terms and conditions of the BEI Resources Material Transfer Agreement (MTA). The MTA is available on our Web site at www.beiresources.org. While BEI Resources uses reasonable efforts to include accurate and up-to-date information on this product sheet, neither ATCC® nor the U.S. Government makes any warranties or representations as to its accuracy. Citations from scientific literature and patents are provided for informational purposes only. Neither ATCC® nor the U.S. Government warrants that such information has been confirmed to be accurate. This product is sent with the condition that you are responsible for its safe storage, handling, use and disposal. ATCC® and the U.S. Government are not liable for any damages or injuries arising from receipt and/ or use of this product. While reasonable effort is made to ensure authenticity and reliability of materials on deposit, the U.S. Government, ATCC®, their suppliers and contributors to BEI Resources are not liable for damages arising from the misidentification or misrepresentation of products. |
References:
|
1. Collins, W. E., Personal Communication.
2. Dissanaike, A. S., P. Nelson and Garnham, P. C. “Two New Malaria Parasites Plasmodium cynomolgi ceylonensis subsp. nov. and Plasmodium fragile sp. nov . from monkeys in Ceylon.” Ceylon J. Med. Sci. 14 (1965): 1-9.
3. “Plasmodium fragile.” In The Primate Malarias. (1971) Eds. G. R. Coatney, W. E. Collins, McW. Warren and P. G. Contacos, CDC: Atlanta, pp. 301-308.
4. Trott, K.A., et al. Evidence for an Increased Risk of Transmission of Simian Immunodeficiency Virus
and Malaria in a Rhesus Macaque Coinfection Model. J Virol. 85 (2011): 11655-63. PubMed: 21917966.
|
|
Citation:
|
Acknowledgment for publications should read “The following reagent was obtained through BEI Resources, NIAID, NIH: Plasmodium fragile, Type Strain, Adapted in Rhesus Monkey, MRA-1322, contributed by William E. Collins.”
|
|
Biosafety Level:
|
1
Appropriate safety procedures should always be used with this material. Laboratory safety is discussed in the following publication: U.S. Department of Health and Human Services, Public Health Service, Centers for Disease Control and Prevention, and National Institutes of Health. Biosafety in Microbiological and Biomedical Laboratories (BMBL). Current Edition. Washington, DC: U.S. Government Printing Office.
|